IMMIX BIOPHARMA, INC.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2022 - Q4(Oct 22 · Nov 22 · Dec 22)
Total Assets
$105M
↑+356.9% +$82Mvs FY2024
Total Liabilities
$11M
↑+13.9% +$1Mvs FY2024
Equity
$94M
↑+607.8% +$81Mvs FY2024
Cash
$94M
↑+431.2% +$76Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $105M | $23M |
| Current Assets | $101M | $20M |
| Cash | $94M | $18M |
| ST Investments | $6M | $0 |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current | $828K | $3M |
| Non-Current Assets | $4M | $3M |
| PPE | $3M | $2M |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $1M | $1M |
| Total Liab+Eq | $105M | $23M |
| Current Liab. | $10M | $9M |
| Accounts Payable | $5M | $5M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $5M | $3M |
| Non-Current Liab. | $934K | $1M |
| Long-Term Debt | $0 | $0 |
| Other LT Liab. | $934K | $1M |
| Equity | $94M | $13M |
| Retained Earnings | $104M | $75M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · IMMX · Comparing FY2025 vs FY2024